1
|
Abbate E, Andrion J, Apel A, Biggs M, Chaves J, Cheung K, Ciesla A, Clark-ElSayed A, Clay M, Contridas R, Fox R, Hein G, Held D, Horwitz A, Jenkins S, Kalbarczyk K, Krishnamurthy N, Mirsiaghi M, Noon K, Rowe M, Shepherd T, Tarasava K, Tarasow TM, Thacker D, Villa G, Yerramsetty K. Optimizing the strain engineering process for industrial-scale production of bio-based molecules. J Ind Microbiol Biotechnol 2023; 50:kuad025. [PMID: 37656881 PMCID: PMC10548853 DOI: 10.1093/jimb/kuad025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Accepted: 08/29/2023] [Indexed: 09/03/2023]
Abstract
Biomanufacturing could contribute as much as ${\$}$30 trillion to the global economy by 2030. However, the success of the growing bioeconomy depends on our ability to manufacture high-performing strains in a time- and cost-effective manner. The Design-Build-Test-Learn (DBTL) framework has proven to be an effective strain engineering approach. Significant improvements have been made in genome engineering, genotyping, and phenotyping throughput over the last couple of decades that have greatly accelerated the DBTL cycles. However, to achieve a radical reduction in strain development time and cost, we need to look at the strain engineering process through a lens of optimizing the whole cycle, as opposed to simply increasing throughput at each stage. We propose an approach that integrates all 4 stages of the DBTL cycle and takes advantage of the advances in computational design, high-throughput genome engineering, and phenotyping methods, as well as machine learning tools for making predictions about strain scale-up performance. In this perspective, we discuss the challenges of industrial strain engineering, outline the best approaches to overcoming these challenges, and showcase examples of successful strain engineering projects for production of heterologous proteins, amino acids, and small molecules, as well as improving tolerance, fitness, and de-risking the scale-up of industrial strains.
Collapse
Affiliation(s)
- Eric Abbate
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Jennifer Andrion
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Amanda Apel
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Matthew Biggs
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Julie Chaves
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Kristi Cheung
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Anthony Ciesla
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Alia Clark-ElSayed
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Michael Clay
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Riarose Contridas
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Richard Fox
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Glenn Hein
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Dan Held
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Andrew Horwitz
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Stefan Jenkins
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | | | | | - Mona Mirsiaghi
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Katherine Noon
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Mike Rowe
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Tyson Shepherd
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Katia Tarasava
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Theodore M Tarasow
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Drew Thacker
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | - Gladys Villa
- Inscripta, Inc., 5720 Stoneridge Dr, Suite 300, Pleasanton, CA 94588, USA
| | | |
Collapse
|
2
|
Van Staalduinen WH, Ganzarain JG, Dantas C, Rodriguez F, Stiehr K, Schulze J, Fernandez-Rivera C, Kelly P, McGrory J, Pritchard C, Berry D, Zallio M, Ciesla A, Ulanicka M, Renaux S, Guzy M. Learning to implement Smart Healthy Age-Friendly Environments. Transl Med UniSa 2021; 23:1-5. [PMID: 34447703 PMCID: PMC8370529 DOI: 10.37825/2239-9747.1021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
To develop trainings on the implementation of smart healthy age-friendly environments for people who aim to support, for example, their parents, their neighbours or local community, there are precautionary measures that have to be taken into account: the role of the facilitator (volunteer or self-employed), the level of skills, the needs of the end-users, training content and methodologies together with the sustainability of the learning. This article examines these aspects, based on desk research and expert interviews in the Smart Healthy Age-Friendly Environments (SHAFE) fields.
Collapse
|
3
|
Chang MR, Ciesla A, Strutzenberg TS, Novick SJ, He Y, Garcia-Ordonez RD, Frkic RL, Bruning JB, Kamenecka TM, Griffin PR. Unique Polypharmacology Nuclear Receptor Modulator Blocks Inflammatory Signaling Pathways. ACS Chem Biol 2019; 14:1051-1062. [PMID: 30951276 DOI: 10.1021/acschembio.9b00236] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Obesity and rheumatic disease are mechanistically linked via chronic inflammation. The orphan receptor TREM-1 (triggering receptor expressed on myeloid cells-1) is a potent amplifier of proinflammatory and noninfectious immune responses. Here, we show that the pan modulator SR1903 effectively blocks TREM-1 activation. SR1903 emerged from a chemical series of potent RORγ inverse agonists, although unlike close structural analogues, it has modest agonist activity on LXR and weak repressive activity (inverse agonism) of PPARγ, three receptors that play essential roles in inflammation and metabolism. The anti-inflammatory and antidiabetic efficacy of this unique modulator in collagen-induced arthritis and diet-induced obesity mouse models is demonstrated. Interestingly, in the context of obesity, SR1903 aided in the maintenance of the thymic homeostasis unlike selective RORγ inverse agonists. SR1903 was well-tolerated following chronic administration, and combined, these data suggest that it may represent a viable strategy for treatment of both metabolic and inflammatory disease. More importantly, the ability of SR1903 to block LPS signaling suggests the potential utility of this unique polypharmacological modulator for treatment of innate immune response disorders.
Collapse
Affiliation(s)
- Mi Ra Chang
- Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Anthony Ciesla
- Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Timothy S. Strutzenberg
- Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Scott J. Novick
- Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Yuanjun He
- Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Ruben D. Garcia-Ordonez
- Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Rebecca L. Frkic
- Institute for Photonics & Advanced Sensing (IPAS), School of Biological Sciences, University of Adelaide, Adelaide, South Australia 5005, Australia
| | - John B. Bruning
- Institute for Photonics & Advanced Sensing (IPAS), School of Biological Sciences, University of Adelaide, Adelaide, South Australia 5005, Australia
| | - Theodore M. Kamenecka
- Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida 33458, United States
| | - Patrick R. Griffin
- Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida 33458, United States
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, Jupiter, Florida 33458, United States
| |
Collapse
|
4
|
Doebelin C, Patouret R, Garcia-Ordonez RD, Chang MR, Dharmarajan V, Novick S, Ciesla A, Campbell S, Solt LA, Griffin PR, Kamenecka TM. Identification of potent RORβ modulators: Scaffold variation. Bioorg Med Chem Lett 2018; 28:3210-3215. [PMID: 30143422 PMCID: PMC6238650 DOI: 10.1016/j.bmcl.2018.08.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Revised: 08/09/2018] [Accepted: 08/13/2018] [Indexed: 11/25/2022]
Abstract
We sought to develop RORβ-selective probe molecules in order to investigate the function of the receptor in vitro and in vivo and its role in the pathophysiology of disease. To accomplish this, we modified a potent dual RORβ/RORγ inverse agonist from the primary literature with the goal of improving selectivity for RORβ vs RORγ. Truncation of the Western portion of the molecule ablated activity at RORγ and led to a potent series of RORβ modulators. Continued exploration of this series investigated alternate replacement cores for the aminothiazole ring. Numerous suitable replacements were found during the course of our SAR investigations and are reported herein.
Collapse
Affiliation(s)
- Christelle Doebelin
- The Scripps Research Institute, Scripps Florida, Department of Molecular Medicine, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Rémi Patouret
- The Scripps Research Institute, Scripps Florida, Department of Molecular Medicine, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Ruben D Garcia-Ordonez
- The Scripps Research Institute, Scripps Florida, Department of Molecular Medicine, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Mi Ra Chang
- The Scripps Research Institute, Scripps Florida, Department of Molecular Medicine, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Venkatasubramanian Dharmarajan
- The Scripps Research Institute, Scripps Florida, Department of Molecular Medicine, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Scott Novick
- The Scripps Research Institute, Scripps Florida, Department of Molecular Medicine, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Anthony Ciesla
- The Scripps Research Institute, Scripps Florida, Department of Molecular Medicine, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Sean Campbell
- The Scripps Research Institute, Scripps Florida, Department of Immunology and Microbiology, 130 Scripps Way #C2A, Jupiter, FL 33458, USA
| | - Laura A Solt
- The Scripps Research Institute, Scripps Florida, Department of Immunology and Microbiology, 130 Scripps Way #C2A, Jupiter, FL 33458, USA
| | - Patrick R Griffin
- The Scripps Research Institute, Scripps Florida, Department of Molecular Medicine, 130 Scripps Way #A2A, Jupiter, FL 33458, USA
| | - Theodore M Kamenecka
- The Scripps Research Institute, Scripps Florida, Department of Molecular Medicine, 130 Scripps Way #A2A, Jupiter, FL 33458, USA.
| |
Collapse
|
5
|
Frkic RL, He Y, Rodriguez BB, Chang MR, Kuruvilla D, Ciesla A, Abell AD, Kamenecka TM, Griffin PR, Bruning JB. Structure-Activity Relationship of 2,4-Dichloro-N-(3,5-dichloro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide (INT131) Analogs for PPARγ-Targeted Antidiabetics. J Med Chem 2017; 60:4584-4593. [PMID: 28485590 DOI: 10.1021/acs.jmedchem.6b01727] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor central to fatty acid and glucose homeostasis. PPARγ is the molecular target for type 2 diabetes mellitus (T2DM) therapeutics TZDs (thiazolidinediones), full agonists of PPARγ with robust antidiabetic properties, which are confounded with significant side effects. Partial agonists of PPARγ, such as INT131 (1), have displayed similar insulin-sensitizing efficacy as TZDs, but lack many side effects. To probe the structure-activity relationship (SAR) of the scaffold 1, we synthesized 14 analogs of compound 1 which revealed compounds with higher transcriptional potency for PPARγ and identification of moieties of the scaffold 1 key to high transcriptional potency. The sulfonamide linker is critical to activity, substitutions at position 4 of the benzene ring A were associated with higher transcriptional activity, substitutions at position 2 aided in tighter packing and activity, and the ring type and size of ring A affected the degree of activity.
Collapse
Affiliation(s)
| | - Yuanjun He
- Department of Molecular Medicine, The Scripps Research Institute, Scripps Florida , Jupiter, Florida 33458, United States
| | | | - Mi Ra Chang
- Department of Molecular Medicine, The Scripps Research Institute, Scripps Florida , Jupiter, Florida 33458, United States
| | - Dana Kuruvilla
- Department of Molecular Medicine, The Scripps Research Institute, Scripps Florida , Jupiter, Florida 33458, United States
| | - Anthony Ciesla
- Department of Molecular Medicine, The Scripps Research Institute, Scripps Florida , Jupiter, Florida 33458, United States
| | - Andrew D Abell
- Institute for Photonics and Advanced Sensing, The University of Adelaide , North Tce, Adelaide, South Australia 5005, Australia
| | - Theodore M Kamenecka
- Department of Molecular Medicine, The Scripps Research Institute, Scripps Florida , Jupiter, Florida 33458, United States
| | - Patrick R Griffin
- Department of Molecular Medicine, The Scripps Research Institute, Scripps Florida , Jupiter, Florida 33458, United States
| | - John B Bruning
- Institute for Photonics and Advanced Sensing, The University of Adelaide , North Tce, Adelaide, South Australia 5005, Australia
| |
Collapse
|
6
|
Bernardis LL, Ciesla A, Bellinger LL. Hypophagic rats with dorsomedial hypothalamic lesions produce lighter and smaller pups with a lower survival rate at weaning than offspring of sham-operated controls. Physiol Behav 1993; 53:59-64. [PMID: 8434071 DOI: 10.1016/0031-9384(93)90011-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Weanling and mature rats with dorsomedial hypothalamic nucleus lesions (DMNL rats) show reduced ponderal and linear growth and hypophagia and hypodipsia in the presence of normal body composition and anabolic hormone levels. The present study was conducted to assess their reproductive/parenting capacity and some offspring parameters. Four groups were used: DMNL mothers and fathers, DMNL mothers and control (SCON) fathers, SCON mothers and DMNL fathers, and SCON mothers and SCON fathers. The constituent rats of each group were bred to yield between 14 and 22 litters. The smallest litter size, litter weight, mean pup weight, percent of live-born and percent of weaned pups and greatest percentage of still-born pups were recorded when both parents were DMNL rats. The latter parents also cannibalized the majority of litters. The above parameters improved when only one parent was a DMNL rat, but this was still significantly below the offspring of SCON x SCON parents. The DMN is not part of the classical hypophysiotropic area (HTA), but earlier findings indicate hyperprolactinemia in DMNL rats. Therefore, the lesion-induced hypophagia during gestation and the postpartum neuroendocrine profile of the DMNL mothers may be the cause of the observed litter deficiencies and poor survival.
Collapse
Affiliation(s)
- L L Bernardis
- Neurovisceral Laboratory, Department of Veterans Affairs Medical Center, Buffalo, NY 14215
| | | | | |
Collapse
|
7
|
|